IMS 2024 | Systemic treatment outcomes in relapsed/refractory POEMS syndrome
Oliver Tomkins, BMBS, BMedSci, DTMH, MRCP(UK), FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, presents the findings of an analysis of systemic treatment outcomes of patients with relapsed/refractory (R/R) POEMS syndrome in the University College London (UCL) POEMS registry. Most patients initially responded to frontline therapy but later experienced relapse, while a small subset of patients were primary refractory. Dr Tomkins also highlights the treatment approaches that led to favorable overall survival (OS) and progression-free survival (PFS) in patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we had 44 patients in the UCLH POEMS registry who were relapsed or refractory. Most patients did respond to frontline therapy and then relapse further down the line. But there were a proportion of patients who were primary refractory in terms of frontline treatment for POEMS syndrome. This is relatively rare and the majority of patients do respond to salvage therapy. But we found that salvage therapy similar to those used for multiple myeloma, so DVd or KRd second-line in the UK, is typically very efficacious and that proceeding to a second melphalan autograft is also feasible in those who had a period of response and also generates a good overall survival and progression-free survival...
So we had 44 patients in the UCLH POEMS registry who were relapsed or refractory. Most patients did respond to frontline therapy and then relapse further down the line. But there were a proportion of patients who were primary refractory in terms of frontline treatment for POEMS syndrome. This is relatively rare and the majority of patients do respond to salvage therapy. But we found that salvage therapy similar to those used for multiple myeloma, so DVd or KRd second-line in the UK, is typically very efficacious and that proceeding to a second melphalan autograft is also feasible in those who had a period of response and also generates a good overall survival and progression-free survival.
Read more...
